Resolves Yes if Resolves Yes if the sponsor announces that the NTLA-2001 phase 3 trial has met its primary endpoint, as confirmed by a press release or updated ClinicalTrials.gov record.
Outcome verified from clinicaltrials.gov.
Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.
NTLA-2001's phase 3 trial for hereditary ATTR amyloidosis met its primary endpoint (mNIS+7 at 12 months) in June 2024, as announced by Intellia in a press release. As of July 2026, this success is confirmed; thus, the event is already resolved in the affirmative.
